IPO

IP Group sees revenue potential from Metsera obesity drug deal

IP Group plc has outlined potential future revenue opportunities from obesity drug candidates developed by Metsera, following Pfizer’s agreement to acquire Metsera for up to $7.3 billion...

IP Group Plc two quoted life sciences portfolio companies receive cash offers

IP Group plc celebrates cash offers for life sciences portfolio firms, expecting significant returns to fuel further investment and share buybacks...
Search

Funds

IPO

IP Group sees revenue potential from Metsera obesity drug deal

IP Group plc has outlined potential future revenue opportunities from obesity drug candidates developed by Metsera, following Pfizer’s agreement to acquire Metsera for up to $7.3 billion...

IP Group Plc two quoted life sciences portfolio companies receive cash offers

IP Group plc celebrates cash offers for life sciences portfolio firms, expecting significant returns to fuel further investment and share buybacks...
Search

Funds

IPO

FTSE 100

Funds